CD4+CD25+ regulatory T-cell therapy.

Abstract:

:Naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) expressing forkhead transcript factor box P3 have been established as a key regulator for the control of autoimmunity. A growing body of experiments in animal models has provided compelling evidence that the adoptive transfer of CD4(+)CD25(+) Tregs can cure many autoimmune and allergic diseases, and appear to induce donor-specific transplantation tolerance. Thus, customer-tailored CD4(+)CD25(+) Tregs have emerged as potential reagents for adoptive cell therapy for individualized medicine. This review discusses recent advances towards that goal.

authors

Jiang S,Lechler RI,Lombardi G

doi

10.1586/1744666X.2.3.387

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

387-92

issue

3

eissn

1744-666X

issn

1744-8409

journal_volume

2

pub_type

杂志文章
  • Agammaglobulinemia: causative mutations and their implications for novel therapies.

    abstract::Agammaglobulinemias are primary (inherited) immunodeficiencies characterized by the lack of functional B-cells and antibodies, and are caused by mutations in genes encoding components of the pre-B-cell or B-cell receptor, or their signaling pathways. The known genetic defects do not account for all agammaglobulinemic ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.850030

    authors: Berglöf A,Turunen JJ,Gissberg O,Bestas B,Blomberg KE,Smith CI

    更新日期:2013-12-01 00:00:00

  • Brodalumab for the treatment of psoriasis.

    abstract:INTRODUCTION:Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monocl...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1246957

    authors: Galluzzo M,D'adamio S,Bianchi L,Talamonti M

    更新日期:2016-12-01 00:00:00

  • Novel therapies for the antiphospholipid syndrome.

    abstract::Antiphospholipid antibodies (aPL Abs) are associated with thrombosis in patients with the antiphospholipid syndrome (APS). There is strong evidence that aPL Abs are pathogenic in vivo from studies in animal models. Furthermore, there are now convincing data indicating that activation of complement is involved in those...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.2.193

    authors: Pierangeli SS

    更新日期:2008-03-01 00:00:00

  • Steroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flares.

    abstract::Evaluation of: Tseng CE, Buyon JP, Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 3623-36...

    journal_title:Expert review of clinical immunology

    pub_type: 评论,杂志文章

    doi:10.1586/1744666X.3.3.267

    authors: Cardiel MH,Almagro RM

    更新日期:2007-05-01 00:00:00

  • What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?

    abstract::Systemic lupus erythematosus is an autoimmune disorder that can affect every organ system and cause a wide range of signs and symptoms. The precise pathogenic mechanism of disease remains uncertain, but it is clearly complex and involves the activation and deregulation of many components of the immune system. Certain ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.1078237

    authors: Vilas-Boas A,Bakshi J,Isenberg DA

    更新日期:2015-01-01 00:00:00

  • Transplantation in highly sensitized patients: challenges and recommendations.

    abstract:INTRODUCTION:Highly sensitized patients awaiting a kidney transplant accrue on the transplant waiting list. The breadth of HLA antibodies in this subpopulation of patients precludes receiving a compatible organ offer through regular allocation within an acceptable time-frame. Areas covered: Several alternative options ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1498335

    authors: Heidt S,Claas FHJ

    更新日期:2018-08-01 00:00:00

  • Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management.

    abstract:INTRODUCTION:Common variable immunodeficiency (CVID) comprises a large heterogeneous group of patients with primary antibody deficiency. Areas covered: The affected patients are characterized by increased susceptibility to infections and low levels of serum immunoglobulin. However, enteropathy, granulomatous organ infi...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1224664

    authors: Azizi G,Abolhassani H,Asgardoon MH,Alinia T,Yazdani R,Mohammadi J,Rezaei N,Ochs HD,Aghamohammadi A

    更新日期:2017-02-01 00:00:00

  • Barriers to successful transplantation of the sensitized patient.

    abstract::Antibody present in the transplant recipient that yields a positive crossmatch with donor cells has long been considered a contraindication and an absolute barrier to transplantation. However, improved methods of antibody detection and characterization have shown that some reactivity with donor cells may be inconseque...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.14

    authors: Zachary AA,Leffell MS

    更新日期:2010-05-01 00:00:00

  • Current status and future prospects for biologic treatments of psoriasis.

    abstract:INTRODUCTION:Biological agents have transformed psoriasis treatment by selectively targeting immune signaling molecules involved in psoriasis pathogenesis. While biologics offer the most effective treatment of moderate to severe psoriasis, they are not without complications. Some patients treated with biologics have po...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1202115

    authors: Cline A,Hill D,Lewallen R,Feldman SR

    更新日期:2016-12-01 00:00:00

  • Immunoregulatory gene polymorphisms and graft-versus-host disease.

    abstract::Graft-versus-host disease (GVHD) remains a significant complication that greatly enhances morbidity and mortality associated with hematopoietic stem cell transplantation. Key immunoregulatory molecules have been implicated in the pathogenesis of GVHD, but the mechanisms by which these molecules affect the incidence an...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.44

    authors: Conway SE,Abdi R

    更新日期:2009-09-01 00:00:00

  • Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease.

    abstract::Probiotics have had many applications in the past few years, and inflammatory conditions of the GI tract--including chronic disorders such as inflammatory bowel disease (IBD)--have received the most attention by investigators. In fact, the experimental basis to expect clinical efficacy of probiotics in IBD is quite ro...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.09.70

    authors: Guandalini S

    更新日期:2010-01-01 00:00:00

  • Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?

    abstract::The course of inflammatory bowel diseases is heterogeneous and varies over time. Therefore, the search for predictive factors has increasingly become the focus of research. Mucosal healing has emerged as an important objective, as evidence indicates that it is associated with improved disease outcome. Nevertheless, ma...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.824675

    authors: Miheller P,Mandel MD,Mullner K,Lakatos PL

    更新日期:2013-09-01 00:00:00

  • Analyzing the frequency and significance of the metabolic syndrome in patients with systemic lupus erythematosus.

    abstract::Evaluation of: Chung CP, Avalos I, Oeser A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristic and cardiovascular risk factors. Ann. Rheum. Dis. 66(2), 208-214 (2007). Systemic lupus erythematosus is associated with higher rates of car...

    journal_title:Expert review of clinical immunology

    pub_type: 评论,杂志文章

    doi:10.1586/1744666X.3.2.121

    authors: Jara LJ,Medina G,Vega-Hinojosa O

    更新日期:2007-03-01 00:00:00

  • Determinants of thyroid autoantibody production in Hashimoto's thyroiditis.

    abstract::Hashimoto's thyroiditis (HT) is the most prevalent thyroid autoimmune disorder, characterized by the presence of specific thyroid autoantibodies (TAb). The development of autoimmunity, including TAb production and clinical presentation of HT, is determined by a complex interplay of genetic susceptibility and several e...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.2.217

    authors: Zaletel K

    更新日期:2007-03-01 00:00:00

  • Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.

    abstract::Conventional myeloablative conditioning regimens prior to hematopoietic cell transplantation (HCT) are associated with significant transplant-related morbidity and mortality in children affected by primary immunodeficiency disorders. Reduced-intensity conditioning regimens have been extensively used without severe acu...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.9

    authors: Chiesa R,Veys P

    更新日期:2012-03-01 00:00:00

  • Tests for evaluating non-immediate allergic drug reactions.

    abstract::Non-immediate drug reactions (NIR) are induced by specific immunological mechanisms and involve the recognition of hapten molecules by the immune system, with the participation of dendritic cells and other antigen-presenting cells. This process is followed by an effector response that can induce several clinical entit...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.966691

    authors: Perkins JR,Ariza A,Blanca M,Fernández TD

    更新日期:2014-11-01 00:00:00

  • Regulatory T cells: the future of autoimmune disease treatment.

    abstract::Introduction: CD4 + T regulatory cells (Tregs) have been described as the most potent immunosuppressive cells in the human body. They have been found to control autoimmunity, and clinical attempts have been made to apply them to treat autoimmune diseases. Some specific pathways utilized by Tregs in the regulation of i...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1620602

    authors: Ryba-Stanisławowska M,Sakowska J,Zieliński M,Ławrynowicz U,Trzonkowski P

    更新日期:2019-07-01 00:00:00

  • Opposing roles of leukotrienes and prostaglandins in fibrotic lung disease.

    abstract::Lung fibrosis is a devastating disease that involves a variable degree of inflammation, alveolar epithelial injury, fibroblast hyperplasia and the deposition of extracellular matrix. Standard therapies that consist of corticosteroids and immunosuppressive agents offer little benefit and most patients experience a prog...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.1.87

    authors: Moore BB,Peters-Golden M

    更新日期:2006-01-01 00:00:00

  • Tacrolimus for the prevention and treatment of rejection of solid organ transplants.

    abstract::Since its introduction to the antirejection armamentarium in 1994, tacrolimus has become the workhorse of transplant professionals for avoidance of solid organ transplant rejection. Not only does tacrolimus have potent immunosuppressive qualities that prevent rejection, but dosing is straight forward and it is general...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2016.1123093

    authors: Scalea JR,Levi ST,Ally W,Brayman KL

    更新日期:2016-01-01 00:00:00

  • Use of rituximab in multiple sclerosis: current progress and future perspectives.

    abstract::In recent years, new insights into the immunological pathways in multiple sclerosis (MS) have been detected. This increasing knowledge has led to more distinct treatment options in modifying the disease course of MS. In 2006, natalizumab, an alpha4-integrin monoclonal antibody, introduced a new era of MS treatment. An...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.5.573

    authors: Reske D,Haupt WF

    更新日期:2008-09-01 00:00:00

  • A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema.

    abstract:INTRODUCTION:HAE is a very debilitating disease that causes significant distress for patients not only during an acute attack but also constant fear for a subsequent attack. It is important to address long-term prophylactic (LTP) therapy to prevent attacks, decrease morbidity and increase the quality of life. When disc...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1750953

    authors: Villavicencio MF,Craig T

    更新日期:2020-05-01 00:00:00

  • Immunobiology of liver xenotransplantation.

    abstract::Pigs are currently the preferred species for future organ xenotransplantation. With advances in the development of genetically modified pigs, clinical xenotransplantation is becoming closer to reality. In preclinical studies (pig-to-nonhuman primate), the xenotransplantation of livers from pigs transgenic for human CD...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.56

    authors: Ekser B,Burlak C,Waldman JP,Lutz AJ,Paris LL,Veroux M,Robson SC,Rees MA,Ayares D,Gridelli B,Tector AJ,Cooper DK

    更新日期:2012-09-01 00:00:00

  • Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic.

    abstract::Introduction: Patients affected by Inborn Errors of Immunity (IEI) represent a potential group-at-risk in the current COVID-19 pandemic. Studies on large and small cohorts of IEI reported a huge variability clinical manifestations associated to SARS-Cov-2, ranging from asymptomatic, mild, moderate/severe to death. A g...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2021.1873767

    authors: Quinti I,Mezzaroma I,Milito C

    更新日期:2021-01-15 00:00:00

  • Adult and pediatric clinical trials of sublingual immunotherapy in the USA.

    abstract::Specific allergen immunotherapy has been practiced for allergic rhinoconjunctivitis for over 100 years and is the only treatment option that is disease modifying. In the USA, immunotherapy is usually administered via subcutaneous injection; this is the only route with a US FDA-approved formulation. There is growing in...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.41

    authors: Park D,Daher N,Blaiss MS

    更新日期:2012-08-01 00:00:00

  • Harnessing immunotherapy for pediatric T-cell malignancies.

    abstract::Pediatric T-cell hematologic malignancies are a diverse group of rare cancers. The most common pediatric T-cell malignancies include T-cell acute lymphoblastic leukemia (T-ALL) and anaplastic large cell lymphoma (ALCL). Although the overall survival rates have improved markedly in recent years, children with relapsed ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1732819

    authors: Diorio C,Teachey DT

    更新日期:2020-04-01 00:00:00

  • Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature.

    abstract::Adherence to medication in patients with rheumatoid arthritis is low, varying from 30 to 80%. Improving adherence to therapy could therefore dramatically improve the efficacy of drug therapy. Although indicators for suboptimal adherence can be useful to identify nonadherent patients, and could function as targets for ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.23

    authors: van den Bemt BJ,Zwikker HE,van den Ende CH

    更新日期:2012-05-01 00:00:00

  • The evolving concept of SLE comorbidities.

    abstract:INTRODUCTION:The survival of SLE patients has improved significantly over the past few decades placing them at increased risk of cardiovascular disease (CVD), malignancies, and osteoporosis, among other comorbidities. The aim of this review was to assess the incidence and prevalence of comorbidities in these patients a...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2017.1327353

    authors: González LA,Alarcón GS

    更新日期:2017-08-01 00:00:00

  • Adalimumab for the treatment of psoriatic arthritis.

    abstract::Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring in 6-39% of patients with psoriasis. Standard therapy of PsA includes nonsteroidal anti-inflammatory drugs, intra-articular steroids and disease-modifying antirheumatic drugs. Failure of standard therapy is an indication for anti-TNF-alpha the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.50

    authors: Poddubnyy DA,Rudwaleit M

    更新日期:2009-11-01 00:00:00

  • Nutrigenetics, nutrigenomics and inflammatory bowel diseases.

    abstract::Inflammatory bowel disease includes ulcerative colitis and Crohn's disease, which are both inflammatory disorders of the gastrointestinal tract. Both types of inflammatory bowel disease have a complex etiology, resulting from a genetically determined susceptibility interacting with environmental factors, including the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.824245

    authors: Ferguson LR

    更新日期:2013-08-01 00:00:00

  • The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

    abstract:INTRODUCTION:Secukinumab, an interleukin-17A (IL-17A) antagonist, is the first non-TNF alpha inhibitor agent licensed for ankylosing spondylitis (AS), which opens up a new era of alternative cytokine targets beyond TNF. Areas covered: This review explores the pathophysiology and scientific evidence behind the use of th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1561281

    authors: Dubash S,Bridgewood C,McGonagle D,Marzo-Ortega H

    更新日期:2019-02-01 00:00:00